Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the target of a large decline in short interest during the month of November. As of November 15th, there was short interest totalling 9,500 shares, a decline of 67.2% from the October 31st total of 29,000 shares. Based on an average trading volume of 22,000 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.2% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on APRE. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Aprea Therapeutics in a report on Monday, November 18th. Wedbush reiterated an “outperform” rating and issued a $11.00 price objective on shares of Aprea Therapeutics in a research note on Tuesday, August 13th.

Insider Buying and Selling

In other news, Director Marc Duey sold 6,462 shares of Aprea Therapeutics stock in a transaction on Friday, October 18th. The stock was sold at an average price of $4.58, for a total transaction of $29,595.96. Following the transaction, the director now owns 233,651 shares in the company, valued at approximately $1,070,121.58. The trade was a 2.69 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Bernd R. Seizinger purchased 10,000 shares of the company’s stock in a transaction that occurred on Friday, October 11th. The shares were acquired at an average cost of $2.68 per share, for a total transaction of $26,800.00. Following the completion of the transaction, the director now directly owns 44,730 shares of the company’s stock, valued at $119,876.40. This trade represents a 28.79 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 42,290 shares of company stock worth $165,096 in the last three months. 12.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Dimensional Fund Advisors LP bought a new stake in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned approximately 0.20% of Aprea Therapeutics at the end of the most recent reporting period. Institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Price Performance

Shares of NASDAQ APRE opened at $2.98 on Thursday. Aprea Therapeutics has a one year low of $2.15 and a one year high of $8.85. The business’s 50-day moving average price is $3.31 and its two-hundred day moving average price is $3.77. The company has a market capitalization of $16.18 million, a P/E ratio of -1.06 and a beta of 0.97.

Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.11. The firm had revenue of $0.35 million for the quarter, compared to analyst estimates of $0.45 million. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%. On average, equities analysts anticipate that Aprea Therapeutics will post -2.55 EPS for the current year.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.